Complete Genomics (GNOM) Posts Narrower than Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Join SI Premium – FREE
Complete Genomics, Inc. (NASDAQ: GNOM) reported Q1 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $3.91 million versus the consensus estimate of $4.84 million.
For earnings history and earnings-related data on Complete Genomics, Inc. (GNOM) click here.
For earnings history and earnings-related data on Complete Genomics, Inc. (GNOM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX's spectrum deal puts SIRI's satellite assets in focus
- New Horizon Aircraft (HOVR) Misses Q1 EPS by 6c
- Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
